Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 23rd Preview)
-
Enveda mega-round drives AI-native pipeline into later-stage development
Enveda secured a $311 million Series E to advance its AI-driven drug discovery pipeline, the company said, with a stated focus on moving three oral candidates in clinical trials toward later-stage development. Two programs, ENV-294 for atopic dermatitis and ENV-308 for metabolic health and weight maintenance, reported positive early clinical results earlier this year. The nature-chemistry platform backing the pipeline, PRISM, generated 17 development candidates to date, Enveda said, and the financing is intended to scale platform execution while expanding the clinical development bench. The company noted its total capital raised since inception now exceeds $845 million. Catalio Capital Management led the round, joined by new investors including Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, Digitalis Ventures, and Alderline Group, alongside existing backers such as Baillie Gifford and Lux Capital. CEO and founder Viswa Colluru framed the round as a shift from platform validation to execution in the clinic. For biotech investors, the deal underscores continued appetite for AI-enabled discovery-to-clinic operators—especially those with measurable human data and a near-to-mid stage pipeline ramp.
-
AI drug-design startup Basecamp lands major funding for in vivo cell therapies
Basecamp Research raised $140 million in an oversubscribed Series C to train its next-generation EDEN foundation models and apply them to in vivo cell therapies across disease areas, the company announced. Basecamp said its approach targets reprogramming inside the body rather than ex vivo manufacturing, aiming to reduce complexity and cost. The funding is intended to support next-generation EDEN model training and continued development of therapeutics designed with large serine recombinases delivered precisely to implement complex DNA changes. Basecamp highlighted preclinical results across multiple modalities and disease indications. Anthropic and other technology-forward investors participated, and Basecamp previously appointed Richard Pearce as chief business officer to expand partnerships with biopharma. CEO Glen Gowers described the work as bringing AI-based therapeutic design closer to patients who lack alternatives. The financing reinforces momentum for AI-native drug discovery companies that can credibly connect model outputs to buildable biology and scalable manufacturing.
-
Immunovant stops Phase 2 IMVT-1402 program after cutaneous lupus failure
Immunovant discontinued IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus after a Phase 2 setback, the company said. The decision closes one pathway for the anti-FcRn antibody approach and narrows near-term options for FcRn-focused autoimmune development. The move follows the same clinical program named by Roivant as IMVT-1402, where Roivant previously reported Phase 2b failure in lupus—highlighting how FcRn antibody strategies can face efficacy hurdles even with a strong mechanistic rationale. For biotech planning, the termination is a reminder that mechanism-driven programs still require durable, clinically meaningful biomarker and symptom improvements across patient subsets. It also alters the competitive landscape for anti-FcRn immunology assets. Investors will likely watch whether other FcRn competitors can demonstrate differentiated clinical profiles that translate into registrational-grade results.
-
Telix and ITM to merge to scale radiopharmaceutical manufacturing and supply
Telix agreed to acquire Isotope Technologies Munich (ITM) in a consolidation move aimed at expanding radiopharmaceutical manufacturing scale and isotope supply control. The deal structure combines an all-stock acquisition with an upfront value cited as $1.65 billion, plus potential contingent payments tied to regulatory approvals and milestones. ITM-11, ITM’s lead candidate—an investigational peptide receptor radionuclide therapy—has completed Phase III testing, Telix said. The combined organization is expected to broaden late-stage pipeline depth while integrating production capabilities for key isotopes used in radioligand therapies. Telix said the transaction would help reduce execution risk by pairing development capabilities with supply infrastructure spanning lutetium-177 and other radionuclides. The companies framed the combination as a strategic response to increasing competitive intensity in radiopharmaceuticals. The merger also adds another data point to ongoing sector consolidation as sponsors seek vertical integration across isotope availability, manufacturing, and clinical development execution.
-
Amgen posts Phase 3 success in Sjögren’s with dazodalibep after Horizon acquisition
Amgen reported preliminary success for dazodalibep, its Horizon Therapeutics-acquired fusion protein, in a Phase 3 trial for Sjögren’s disease. The company said the candidate met the primary objective in a mid-to-late stage evaluation, positioning the program as a potential first therapy in a common autoimmune indication with limited approved options. The readout suggests the program could compete with existing immunology approaches and sets up further regulatory discussions depending on final datasets and the second Phase 3 trial requirement. Amgen has placed the asset within a broader autoimmune portfolio where late-stage catalysts can materially change valuation. The Sjögren’s market is crowded with investigational efforts but remains underserved for durable symptom control, and a positive Phase 3 can quickly shift competitive expectations. For the sector, the Horizon-to-Amgen integration continues to pay off if the remaining Phase 3 effort confirms the efficacy profile and maintains a tolerable safety signal.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.